Gene therapy for alpha-1 antitrypsin deficiency: an update

Area of Science:

• Genetics
• Molecular Biology
• Medical Science

Background:

• Alpha-1 antitrypsin deficiency (AATD) results from impaired alpha-1 antitrypsin (AAT) protein synthesis and secretion, causing liver accumulation and lung damage.
• AATD, a monogenic disease, is a prime candidate for gene therapy due to its single-gene cause.
• Existing therapies for AATD are limited, particularly for liver and pulmonary manifestations.

Approach:

• Reviewing the historical development, challenges, and successes of AATD gene therapy.
• Discussing emerging strategies and technologies for AATD treatment, including gene introduction, silencing, and correction.
• Highlighting the critical need for safe and effective AAT protein expression in AATD gene therapy.

Key Points:

• Gene therapy aims to correct the genetic basis of AATD to normalize AAT protein function.
• Technological advancements in gene editing and delivery are crucial for therapeutic success.
• Safe and clinically effective AAT expression remains the primary hurdle in AATD gene therapy development.

Conclusions:

• Gene therapy holds significant potential for treating AATD, addressing unmet needs in pulmonary and liver disease.
• Continued research and technological innovation are essential to overcome current challenges in AATD gene therapy.
• Emerging gene-based strategies offer new hope for patients with AATD.